Clinical Trials
CANCER RESEARCH
Click here to download a printable copy of this information.
Breast
Principal Investigator: Jane Skelton, MD
Sponsor/Study ID: Agendia FLEX
Protocol Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
National Clinical Trials Identifier: NCT03053193
Principal Investigator: Naomi Dempsey, MD
Sponsor/Study ID: Alliance A011801
Protocol Description: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatin
National Clinical Trials Identifier: NCT04457596
Gastrointestinal
Principal Investigator: Stephen Grabelsky, MD
Sponsor/Study ID: Astellas 8951-CL-5201
Protocol Description: A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
National Clinical Trials Identifier: NCT03816163
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Novocure EF-27
Protocol Description: Panova-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
National Clinical Trials Identifier: NCT03377491
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Signatera/BESPOKE 20-041-NCP
Protocol Description:
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Open to stage I and IV as of 7/11/22. Stage II and III on hold for analysis
National Clinical Trials Identifier: NCT04264702
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Gritstone GO-010
Protocol Description: A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
National Clinical Trials Identifier: NCT05141721
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Aravive AVB500-PC-005
On hold until opening of Phase 2
Protocol Description: A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel and Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma
National Clinical Trials Identifier: NCT04983407
Lymphoma/Leukemia
Principal Investigator: Spencer Bachow, MD
Sponsor/Study ID: LOXO-BTK-20020
Protocol Description: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-321).
National Clinical Trials Identifier: NCT04666038
GENITOURINARY
Principal Investigator: Alan Koletsky, MD
Sponsor/Study ID: MSKCC / Pfizer C16-174
Protocol Description: DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
National Clinical Trials Identifier: NCT03574571
HEAD AND NECK
Principal Investigator: Michael Kasper, MD
Sponsor/Study ID: Monopar Therapeutics MNPR-301-001
Protocol Description: A Phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer
National Clinical Trials Identifier: NCT04648020
SKIN
Principal Investigator: Hilary Gomolin, MD
Sponsor/Study ID: HUYA Bioscience International HBI-8000-303
Protocol Description: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
National Clinical Trials Identifier: NCT04674683
Lung
Principal Investigator: Matthen Mathew, MD
Sponsor/Study ID: Merck MK7684A-003
Protocol Description:
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with
Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy
as First Line Treatment for Participants With PD-L1 Positive Metastatic
Non-Small Cell Lung Cancer
PI change in process
National Clinical Trials Identifier: NCT04738487
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Biodesix BDX-00146
Protocol Description: An Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer
National Clinical Trials Identifier: NCT03289780
Principal Investigator: Matten Mathew, MD
Sponsor/Study ID: Merck MK-7684A-008
Protocol Description: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
National Clinical Trials Identifier: NCT05224141
Principal Investigator: Matten Mathew, MD
Sponsor/Study ID: AstraZeneca SAVANNAH D5084C00007
Protocol Description:
A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination
with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or
Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment
with Osimertinib (The SAVANNAH Study)
Pending to re-open on Protocol V7.0
National Clinical Trials Identifier: NCT03778229
General Oncology
Principal Investigator:
Sponsor/Study ID: City of Hope National Medical Center 96144
Protocol Description: Molecular Genetic Studies of Cancer Patients and Their Relatives
National Clinical Trials Identifier:
No NCT # GENETICS STUDY
- Personal history or family history of cancer suggestive of presence of an inherited predisposition
- In a group known or suspected to have increased risk of carrying genetic alteration or of sustaining exposure that would place them at risk of cancer
- Willing historian to provide information or access
- Young age cancer diagnosis
- Multiple primary neoplasms in affected member
- Presence of rare tumor types in family
- Congenital malformations
- Any other family clustering of cancer
- Any other cancer-predisposing genetic disease/conditions
Neurology and Neuro-Oncology
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: Denovo DB102-01
Protocol Description: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
National Clinical Trials Identifier: NCT03776071
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: National Cancer Institute/Alliance N0577
Protocol Description: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
National Clinical Trials Identifier: NCT00887146
Principal Investigator:
Sponsor/Study ID: Scripps 1R01CA229737-07
Protocol Description:
Clinical Translation of Precision Medicine Testing Utilizing 3 Dimensional
Primary Tumor Cell Culture
Enrollment paused pending revised protocol
National Clinical Trials Identifier:
No NCT #
- Patients scheduled to have surgery for removal of brain tumor.
- Age: 18 years and older.
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: Alliance A071701
Protocol Description: Genetic Testing in Guiding Treatment for Patients with Brain Metastases
National Clinical Trials Identifier: NCT03994796
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: Alliance A071401
Protocol Description:
Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas
With SMO/AKT/NF2/CDK Pathway Mutations
Effective 10/03/2022 abemaciclib cohort closed to accrual. AKT1, PIK3CA,
PTE cohorts remain open to accrual
National Clinical Trials Identifier: NCT02523014
Principal Investigator: Samuel Richter, MD
Sponsor/Study ID: Canadian Clinical Trial Group (CCTG) CE.7
Protocol Description: A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
National Clinical Trials Identifier: NCT03550391
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: NRG Oncology NRG-BN010
Protocol Description:
A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and
Impact on the Tumor Microenvironment of the Combination of Tocilizumab,
Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent
Glioblastoma
Accrual opened to the safety run-in portion at dose level 2 (tocilizumab 8 mg/kg).
National Clinical Trials Identifier: NCT04729959
Principal Investigator: Sajeel Chowdhary, MD
Sponsor/Study ID: Novocure EF-32 (TRIDENT)
Protocol Description: A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
National Clinical Trials Identifier: NCT04471844
SOLID TUMORS
Principal Investigator: Warren Brenner, MD
Sponsor/Study ID: Medicenna MDNA11-01
Protocol Description: A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors ABILITY (A Beta-only IL-2 ImmunoTherapY) STUDY
National Clinical Trials Identifier: NCT05086692